Pyelonephritis in Pregnancy
Conditions
Keywords
pyelonephritis, pregnancy, cefuroxime
Brief summary
The goal of this clinical trial is to compare rates of cure in pregnant women with pyelonephritis. The main question aims to answer: Can we treat pyelonephritis in pregnancy with oral cefuroxime alone? Pregnant women with pyelonephritis treated with intravenous cefuroxime will be the comparator. Participants will be asked to accept participation in the study and will be randomly allocated to one of the two arms: * Intravenous cefuroxime 750 mg every 8 hours + oral placebo every 12 hours * Oral cefuroxime 500 mg every 12 hours + intravenous saline solution every 8 hours
Detailed description
Urinary tract infections are common during pregnancy and can lead to pyelonephritis, a condition associated with morbidity in both the fetus and the pregnant woman. At HCPA, intravenous cefuroxime has been used until the antibiogram results from the pregnant woman's urine culture are available. However, this treatment requires hospitalization, which is financially burdensome and can affect the well-being of the pregnant woman. Despite this, there are not enough studies to investigate the use of oral cefuroxime as an initial treatment. Objective: To compare the efficacy of cefuroxime administered orally versus intravenously in curing pyelonephritis during pregnancy, aiming to test the non-inferiority of the oral treatment. Method: A randomized, prospective, triple-blind, two-arm study will be conducted. Pregnant women with pyelonephritis who agree to participate in the study at the time of hospitalization will receive the treatment: I) cefuroxime axetil 750mg IV every 8 hours and a placebo capsule 500mg; or II) 500mg orally every 12 hours and IV saline solution. These patients will be followed until the outcome is determined. After 48 hours in good clinical condition, the patients will be discharged and will continue treatment with cefuroxime axetil 500mg orally every 12 hours for 14 days. To analyze the difference in means and proportions with confidence intervals, Student's t-test will be performed, while nominal data will be analyzed using the chi-square test.
Interventions
DRUGCefuroxime
Intravenous cefuroxime 750 mg every 8 hours
Oral cefuroxime 500 mg every 12 hours
Sponsors
Hospital de Clinicas de Porto Alegre
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Masking description
Patients, care providers and investigators will not be aware of the treatment arm. Statistical analysis will be performed using pre-established criteria to access coded treatment
Intervention model description
Randomized, parallel, non-inferiority trial
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 48 Years
Healthy volunteers
No
Inclusion criteria
* Pregnant women aged 18 years or older and less than 20 weeks of gestational age, determined by ultrasound or the date of last menstruation, who come to the HCPA emergency department with a clinical diagnosis of pyelonephritis in pregnancy, defined as: * Presence of lower back pain associated with * Dysuria with leukocyturia, or hematuria or nitrite in the urine test with at least one of the criteria below: * Leukocytosis (\> 14,000 leukocytes/mL) * Warm extremities, thready pulse, and tachycardia (HR \> 110 bpm) * Cyanosis and/or pallor * Tachypnea (RR \> 30 breaths/min) * Arterial hypotension (SBP \< 90mmHg) * Positive costovertebral angle tenderness * Urine culture with colony growth * Hyperthermia (≥ 37.8°C)
Exclusion criteria
* Do not wish to participate in the project. * Used antimicrobials prior to hospitalization (3-day period). * those who are allergic to cefuroxime. * Have a urine culture antibiogram resistant to cefuroxime AND absence of clinical improvement (in this case, will be excluded as modified intention to treat). * Have a diagnosis other than pyelonephritis, for example, appendicitis. * those in septic shock, defined as: * the need for vasopressor to maintain a mean arterial pressure ≥ 65 mmHg and lactate \> 2 mmol/l or 2 points on qSOFA. qSOFA will be considered positive when at least two of the following clinical criteria are present: * Respiratory rate greater than or equal to 22 breaths per minute; * Altered level of consciousness (Glasgow Coma Scale score less than 15); * Systolic blood pressure less than or equal to 100 mmHg.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical improvement | 3 days | No fever, improvement of lower back pain |
| Negative urine culture | 21 days | No growth of pathogenic bacteria in the urine culture |
Countries
Brazil
Contacts
Primary ContactRicardo F Savaris, PhD
Outcome results
None listed